Fernández-Cano, M.C.; Fernández-Cano, A.J.; MartÃn-RodrÃguez, M.M.; Sánchez-Capilla, A.D.; Cabello-Tapia, M.J.; Redondo-Cerezo, E.
Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study. J. Clin. Med. 2024, 13, 556.
https://doi.org/10.3390/jcm13020556
AMA Style
Fernández-Cano MC, Fernández-Cano AJ, MartÃn-RodrÃguez MM, Sánchez-Capilla AD, Cabello-Tapia MJ, Redondo-Cerezo E.
Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study. Journal of Clinical Medicine. 2024; 13(2):556.
https://doi.org/10.3390/jcm13020556
Chicago/Turabian Style
Fernández-Cano, MarÃa Carmen, Antonio Jesús Fernández-Cano, MarÃa Mar MartÃn-RodrÃguez, Antonio Damián Sánchez-Capilla, MarÃa José Cabello-Tapia, and Eduardo Redondo-Cerezo.
2024. "Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study" Journal of Clinical Medicine 13, no. 2: 556.
https://doi.org/10.3390/jcm13020556
APA Style
Fernández-Cano, M. C., Fernández-Cano, A. J., MartÃn-RodrÃguez, M. M., Sánchez-Capilla, A. D., Cabello-Tapia, M. J., & Redondo-Cerezo, E.
(2024). Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study. Journal of Clinical Medicine, 13(2), 556.
https://doi.org/10.3390/jcm13020556
